



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0


F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

BRN801c : Breast normal tissue with breast cancer tissue array, including pathology grade, TNM and clinical stage, 80 cases/80 cores, replacing BRN801b

| | | |
|--------------------|---|---|
| Microarray Panel | Breast normal tissue with breast carcinoma tissue microarray, containing 66 cases of adjacent normal or cancer adjacent tissue, 4 normal tissue, plus 10 invasive carcinoma of no special type, single core per case | |
| Cores | 80 | <div>BRN801c H&E</div>  |
| Cases | 80 | |
| Row number | 8 | |
| Column number | 10 | |
| Core Diameter (mm) | 1.5 | |
| Thickness (µm) | 5 | |
| Quality Control | H&E and IHC confirmed | |
| Tissue Array Type | FFPE | |
| Species | Human | |
| Applications | Routine histology procedures including Immunohistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found at our support page. | |
| Notes | <p>1. TMA slides were sectioned and stored at 4°C and may not be fresh cut, but still suitable for IHC. Please request fresh cut if experiment involves phospho-specific antibodies, RNA studies, FISH or ISH, etc. A minimum of 3 slides per TMA must be purchased to cover the cost of trimming for fresh sectioning. 2. Most TMA slides were not coated with an extra layer of paraffin (tissue cores can be easily seen on the glass). To prevent tissue detachment during antigen retrieval, unbaked slides must be baked for at least 30 to 120 minutes at 60°C. before putting into xylene for de-paraffinization. Baked slides were sent out baked for 2 hours.</p> <p>In the following specsheet, “*” means invalid core; “-” means no applicable or negative in IHC markers.</p> | |

| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
|---|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| A | Bre | AT | Bre | Bre | Bre | AT | Bre | Bre | Bre | Bre |
| B | Bre | Bre | Bre | Bre | Bre | Bre | Bre | Bre | AT | Bre |
| C | Bre | Bre | Bre | Bre | Bre | AT | AT | Bre | AT | AT |
| D | Bre | Bre | Bre | AT | Bre | Bre | AT | Bre | Bre | Bre |
| E | Bre | Bre | Bre | Bre | AT | Bre | Bre | Bre | Bre | AT |
| F | Bre | AT | Bre | Bre | Bre | Bre | AT | Bre | Bre | Bre |
| G | Bre | Bre | Bre | Bre | Bre | Bre | Bre | Bre | Bre | Bre |
| H | Bre | Bre | Bre | Bre | Bre | Bre | Bre | Bre | Bre | Bre |

Legend: Bre - Breast

AT - AT, Bre - Malignant tumor (stage IIA), Bre - Malignant tumor (stage IIB), Bre - Malignant tumor (stage IIIA), Bre - Malignant tumor (stage IIIB), Bre - NAT, Bre - Normal tissue

, tissue IDs are available in exported Excel files.

| Pos. | No. | Age | Sex | Organ/Anatomic Site | Pathology diagnosis | TNM | Grade | Stage | Type | Image |
|------|-----|-----|-----|---------------------|---|-----|-------|-------|------|-------|
| A1 | 1 | 45 | F | Breast | Adjacent normal breast tissue | - | - | - | NAT | |
| A2 | 2 | 45 | F | Breast | Cancer adjacent breast tissue (ductal ectasia) | - | * | - | AT | |
| A3 | 3 | 47 | F | Breast | Adjacent normal breast tissue (sparse) | - | * | - | NAT | |
| A4 | 4 | 49 | F | Breast | Adjacent normal breast tissue | - | - | - | NAT | |
| A5 | 5 | 53 | F | Breast | Adjacent normal breast tissue | - | - | - | NAT | |
| A6 | 6 | 31 | F | Breast | Cancer adjacent breast tissue | - | - | - | AT | |
| A7 | 7 | 51 | F | Breast | Adjacent normal breast tissue | - | - | - | NAT | |
| A8 | 8 | 43 | F | Breast | Adjacent normal breast tissue | - | - | - | NAT | |
| A9 | 9 | 44 | F | Breast | Adjacent normal breast tissue | - | - | - | NAT | |
| A10 | 10 | 42 | F | Breast | Adjacent normal breast tissue | - | - | - | NAT | |
| B1 | 11 | 39 | F | Breast | Adjacent normal breast tissue (duct) | - | * | - | NAT | |
| B2 | 12 | 43 | F | Breast | Adjacent normal breast tissue | - | - | - | NAT | |
| B3 | 13 | 50 | F | Breast | Adjacent normal breast tissue | - | - | - | NAT | |
| B4 | 14 | 41 | F | Breast | Adjacent normal breast tissue | - | - | - | NAT | |
| B5 | 15 | 42 | F | Breast | Adjacent normal breast tissue | - | - | - | NAT | |
| B6 | 16 | 45 | F | Breast | Adjacent normal breast tissue (sparse) | - | * | - | NAT | |
| B7 | 17 | 51 | F | Breast | Adjacent normal breast tissue | - | - | - | NAT | |
| B8 | 18 | 37 | F | Breast | Adjacent normal breast tissue | - | - | - | NAT | |
| B9 | 19 | 50 | F | Breast | Cancer adjacent breast tissue | - | - | - | AT | |
| B10 | 20 | 49 | F | Breast | Adjacent normal breast tissue (fibrofatty tissue) | - | * | - | NAT | |
| C1 | 21 | 48 | F | Breast | Adjacent normal breast tissue | - | - | - | NAT | |
| C2 | 22 | 56 | F | Breast | Adjacent normal breast tissue | - | - | - | NAT | |

| | | | | | | | | | | |
|-----|----|----|---|--------|---|---------|------|------|-----------|--|
| C3 | 23 | 43 | F | Breast | Adjacent normal breast tissue | - | - | - | NAT | |
| C4 | 24 | 44 | F | Breast | Adjacent normal breast tissue | - | - | - | NAT | |
| C5 | 25 | 36 | F | Breast | Adjacent normal breast tissue (fibrofatty tissue) | - | * | - | NAT | |
| C6 | 26 | 40 | F | Breast | Cancer adjacent breast tissue (fibrofatty tissue) | - | * | - | AT | |
| C7 | 27 | 34 | F | Breast | Cancer adjacent breast tissue | - | - | - | AT | |
| C8 | 28 | 40 | F | Breast | Adjacent normal breast tissue | - | - | - | NAT | |
| C9 | 29 | 40 | F | Breast | Cancer adjacent breast tissue | - | - | - | AT | |
| C10 | 30 | 40 | F | Breast | Cancer adjacent breast tissue | - | - | - | AT | |
| D1 | 31 | 49 | F | Breast | Adjacent normal breast tissue (fibrofatty tissue) | - | * | - | NAT | |
| D2 | 32 | 48 | F | Breast | Adjacent normal breast tissue | - | - | - | NAT | |
| D3 | 33 | 43 | F | Breast | Adjacent normal breast tissue | - | - | - | NAT | |
| D4 | 34 | 57 | F | Breast | Cancer adjacent breast tissue | - | - | - | AT | |
| D5 | 35 | 35 | F | Breast | Adjacent normal breast tissue | - | - | - | NAT | |
| D6 | 36 | 38 | F | Breast | Adjacent normal breast tissue | - | - | - | NAT | |
| D7 | 37 | 48 | F | Breast | Adjacent normal breast tissue | - | - | - | NAT | |
| D8 | 38 | 52 | F | Breast | Cancer adjacent breast tissue (fibrofatty tissue) | - | * | - | AT | |
| D9 | 39 | 41 | F | Breast | Adjacent normal breast tissue | - | - | - | NAT | |
| D10 | 40 | 40 | F | Breast | Adjacent normal breast tissue | - | - | - | NAT | |
| E1 | 41 | 30 | F | Breast | Adjacent normal breast tissue | - | - | - | NAT | |
| E2 | 42 | 50 | F | Breast | Adjacent normal breast tissue (fibrofatty tissue) | - | * | - | NAT | |
| E3 | 43 | 45 | F | Breast | Adjacent normal breast tissue | - | - | - | NAT | |
| E4 | 44 | 42 | F | Breast | Adjacent normal breast tissue (fibrofatty tissue) | - | * | - | NAT | |
| E5 | 45 | 48 | F | Breast | Cancer adjacent breast tissue | - | - | - | AT | |
| E6 | 46 | 48 | F | Breast | Adjacent normal breast tissue | - | - | - | NAT | |
| E7 | 47 | 53 | F | Breast | Adjacent normal breast tissue | - | - | - | NAT | |
| E8 | 48 | 54 | F | Breast | Adjacent normal breast tissue | - | - | - | NAT | |
| E9 | 49 | 45 | F | Breast | Adjacent normal breast tissue | - | - | - | NAT | |
| E10 | 50 | 38 | F | Breast | Cancer adjacent breast tissue (fibrofatty tissue) | - | * | - | AT | |
| F1 | 51 | 52 | F | Breast | Adjacent normal breast tissue | - | - | - | NAT | |
| F2 | 52 | 48 | F | Breast | Cancer adjacent breast tissue | - | - | - | AT | |
| F3 | 53 | 46 | F | Breast | Adjacent normal breast tissue | - | - | - | NAT | |
| F4 | 54 | 54 | F | Breast | Adjacent normal breast tissue | - | - | - | NAT | |
| F5 | 55 | 45 | F | Breast | Adjacent normal breast tissue (fibrofatty tissue) | - | * | - | NAT | |
| F6 | 56 | 48 | F | Breast | Adjacent normal breast tissue | - | - | - | NAT | |
| F7 | 57 | 41 | F | Breast | Adjacent normal breast tissue (fibrofatty tissue) | - | * | - | NAT | |
| F8 | 58 | 53 | F | Breast | Cancer adjacent breast tissue | - | - | - | AT | |
| F9 | 59 | 46 | F | Breast | Adjacent normal breast tissue | - | - | - | NAT | |
| F10 | 60 | 42 | F | Breast | Adjacent normal breast tissue | - | - | - | NAT | |
| G1 | 61 | 38 | F | Breast | Adjacent normal breast tissue | - | - | - | NAT | |
| G2 | 62 | 42 | F | Breast | Adjacent normal breast tissue (fibrofatty tissue) | - | * | - | NAT | |
| G3 | 63 | 44 | F | Breast | Adjacent normal breast tissue | - | - | - | NAT | |
| G4 | 64 | 35 | F | Breast | Adjacent normal breast tissue | - | - | - | NAT | |
| G5 | 65 | 52 | F | Breast | Adjacent normal breast tissue | - | - | - | NAT | |
| G6 | 66 | 43 | F | Breast | Adjacent normal breast tissue | - | - | - | NAT | |
| G7 | 67 | 50 | F | Breast | Breast tissue | - | - | - | Normal | |
| G8 | 68 | 21 | F | Breast | Breast tissue | - | - | - | Normal | |
| G9 | 69 | 39 | F | Breast | Breast tissue | - | - | - | Normal | |
| G10 | 70 | 54 | F | Breast | Breast tissue | - | - | - | Normal | |
| H1 | 71 | 29 | F | Breast | Invasive carcinoma of no special type | T2N0M0 | 1 | IIA | Malignant | |
| H2 | 72 | 47 | F | Breast | Invasive carcinoma of no special type | T4bN0M0 | 1 | IIIB | Malignant | |
| H3 | 73 | 42 | F | Breast | Invasive carcinoma of no special type | T3N0M0 | 1--2 | IIB | Malignant | |
| H4 | 74 | 48 | F | Breast | Invasive carcinoma of no special type | T4N1M0 | 2 | IIIB | Malignant | |
| H5 | 75 | 54 | F | Breast | Invasive carcinoma of no special type | T2N1M0 | 3 | IIB | Malignant | |
| H6 | 76 | 65 | F | Breast | Invasive carcinoma of no special type (blank) | T1N2M0 | * | IIIA | Malignant | |
| H7 | 77 | 60 | F | Breast | Invasive carcinoma of no special type | T2N0M0 | 2 | IIA | Malignant | |
| H8 | 78 | 53 | F | Breast | Invasive carcinoma of no special type | T3N0M0 | 3 | IIB | Malignant | |
| H9 | 79 | 52 | F | Breast | Invasive carcinoma of no special type | T1N1M0 | 2 | IIA | Malignant | |
| H10 | 80 | 45 | F | Breast | Invasive carcinoma of no special type | T3N0M0 | 2 | IIB | Malignant | |
| - | 0 | 55 | F | liver | Hepatocellular liver cancer (tissue marker) | T3N0M0 | 3 | | Malignant | |

AMS BIO | www.amsbio.com | info@amsbio.com

AMS BIO LLC
USA & Canada
1035 Cambridge Street,
Cambridge, MA 02141
T: +1 (617) 945-5033 or
T: +1 (800) 987-0985
F: +1 (617) 945-8218

AMS BIO Europe BV
EU
Berenkoog 41,
1822 BH Alkmaar,
Netherlands
T: +31 (0) 72 8080244
F: +31 (0) 72 8080142

AMS Biotechnology (Europe) Ltd
UK & Rest of the World
184 Park Drive, Milton Park
Abingdon OX14 4SE
T: +44 (0) 1235 828 200
F: +44 (0) 1235 820 482

AMS Biotechnology (Europe) Ltd
Switzerland
Via Lisano 3,
CH-6900 Massagno
T: +41 (0) 91 604 55 22
F: +41 (0) 91 605 17 85

AMS BIO Europe BV
Deutschland
T: +49 (0) 69 779099
F: +49 (0) 69 13376880